One treatment strategy of the combination of immune CPIs, such as anti-PD-1 and anti-CTLA-4, has been instituted to bring immune cells into the tumor compartment and prevent them from being suppressed on arrival. This evidence concerns the gene CTLA4 and neoplasm.